Cardiac Biomarkers Market Size

Cardiac Biomarkers Market size was valued at USD 10.61 Billion in 2023 and is poised to grow from USD 11.95 Billion in 2024 to USD 31.05 Billion by 2032, growing at a CAGR of 12.67% during the forecast period (2025-2032).

'Abbott ', 'QuidelOrtho Corporation ', 'Siemens AG ', 'F. Hoffmann-La Roche Ltd. ', 'Danaher Corporation ', 'Biomérieux SA ', 'Bio-Rad Laboratories, Inc. ', 'Randox Laboratories Ltd. ', 'Creative Diagnostics ', 'Life Diagnostics ', 'Thermo Fisher Scientific ', 'Becton, Dickinson and Company ', 'DiaSorin ', 'Myriad RBM ', 'Mindray Medical International Limited  ', 'ReLIA Diagnostic Systems ', 'Merck KGaA ', 'Quanterix Corporation ', 'Eurofins Scientific ', 'Inova Diagnostics'

Focus on Preventive Healthcare and Early Diagnosis

Growing Use of Multi-Biomarker Panels: Recent years have witnessed increased use of panels of biomarkers. This inclination towards biomarker panels rather than single markers is trending in the market. These panels offer a highly exhaustive evaluation of cardiovascular risks relating to stress, cardiac injury, and inflammation. Multi-biomarkers methods are currently being explored to improve risk stratification, mainly in complicated cases where single biomarkers may not offer enough data.

Geographically, North America is the dominating region among others and is expected to lead over the forecast period owing to improved healthcare infrastructure with advanced diagnostic technologies and increased adoption of novel medical solutions. Also, the rising incidences of heart disorders in the region are rigorously demanding effective diagnostic solutions. Regional growth is further impacted by robust R&D along with strong network of clinical and academic research institutes, driving improvements in biomarker technologies. The leading players operating in the region include Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Beckman Coulter, Quidel Corporation, and more.